Spinal muscular atrophy: from gene to therapy

Area of Science:

• Neurology
• Genetics
• Molecular Biology

Background:

• Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder.
• The disease results from homozygous loss of the survival motor neuron gene 1 (SMN1).
• A similar gene, SMN2, influences SMA severity due to a mutation causing exon 7 skipping, leading to reduced functional protein production.

Purpose of the Study:

• To explore therapeutic strategies for SMA.
• To investigate the potential of histone deacetylase inhibitors (HDACi) like valproic acid (VPA) and 4-phenylbutyrate (PBA) in increasing SMN protein levels.
• To evaluate the in vivo activation of SMN gene expression in SMA patients and carriers treated with VPA.

Main Methods:

• Review of existing literature on SMA molecular basis and therapeutic approaches.
• Analysis of studies investigating the effects of VPA and PBA on SMN2 gene expression and protein levels.
• Examination of clinical trial data regarding VPA and PBA in SMA patients.

Main Results:

• HDAC inhibitors (VPA, PBA) have demonstrated the ability to increase SMN2-derived RNA and protein levels.
• In vivo activation of the SMN gene has been observed in VPA-treated SMA patients and carriers.
• Clinical trials are ongoing to assess the impact of VPA and PBA on motor function in SMA patients.

Conclusions:

• Therapeutic strategies for SMA focus on increasing functional SMN protein.
• VPA and PBA are promising HDAC inhibitors for boosting SMN levels.
• Further clinical investigation is necessary to confirm the efficacy of VPA and PBA in improving motor function for SMA patients.